Press release

€1.4 million capital increase by Acticor Biotech

Funding used to step up development of its first-in-class drug candidate for the emergency treatment of strokes

Paris, 11 July 2016 – Acticor Biotech, biotechnology company which is developing an anti-thrombotic agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform (€740,000), from research association ARMESA (€500,000) and from business angels (€170,000).

Acticor Biotech's ACT-017 drug candidate represents a **major innovation in the emergency treatment of ischemic strokes.** It is a first-in-class candidate that inhibits a new target protein, the glycoprotein VI, which is specifically responsible for the growth of blood clots during a stroke. ACT-017 is intended to be used alone or in combination with Alteplase®, the only emergency treatment currently available, which is given to fewer than 10% of patients in the four and a half hours after the first symptoms appearing.

The capital increase will enable Acticor Biotech to continue pre-clinical development and produce initial batches of ACT-017.

Gilles Avenard, CEO of Acticor Biotech, said *"the emergency treatment of ischemic strokes represents a major medical need, since over 600,000 patients per year are affected in Europe. The treatment of ischemic strokes, either in combination with Alteplase® or after Alteplase®, must be without bleeding risk. In vitro and in vivo testing of ACT-017 have confirmed results already published, suggesting that we have a drug candidate that will eventually be possible to admin just after the first symptoms appear."*

Joachim Dupont, co-founder of Anaxago and director of Acticor Biotech, said *"this second funding round for Acticor Biotech, organized via our platform, is 30% larger than the first round and provides further validation of the crowdfunding model for the healthcare sector. It shows the interest of investors for Acticor*

biotech developments in stroke treatment, and their desire to support the development of innovative solutions to major unresolved public health problems."

According to the WHO, 23 million people around the world will suffer a stroke in 2030.

About Ischemic stroke - http://acticor-biotech.com/en/stroke/
Stroke affects 400,000 people in France (including 130,000 new cases each year) and 15 million worldwide (1.5 million annually). Third cause of mortality in men and second in women, it represents the leading cause of acquired handicap in adults. Occurrence of stroke is increasing with the growth of the aging population.

About ACT-017 - http://acticor-biotech.com/en/technology/
Stroke is the second most common cause of death in Europe, causing 1.1 million deaths each year and is the leading cause of acquired handicap in adults. Occurrence of stroke is increasing with the growth of the aging population: 800,000 new or recurrent strokes occur per year in the US and about 1 million in Europe.

ACT-017 is positioned as a first-line anti-thrombotic treatment, to be combined or not with thrombolysis or mechanical thrombectomy, in the therapy of acute ischemic stroke. The Fab targets GPVI, a platelet transmembrane protein which is essential to thrombus formation and growth in artery but not required for physiological hemostasis. Animal models and observation of patients naturally deficient in GPVI (by autoimmunity or genetic mutation) show that GPVI inhibition does not trigger bleeding risk.

About ACTICOR-BIOTECH - http://acticor-biotech.com/en/company/
Acticor Biotech is an Inserm spin-off. Founded in late 2013, the company's mission is primarily to develop the anti-GPVI antibody as a platelet-aggregation inhibitor for acute thrombotic pathologies. Acticor Biotech's project is based on scientific research from two Inserm units and was lead by Drs Martine Jandrot-Perrus (U1148) and by Pr. Philippe Billiald from the Institut Paris-Sud d'Innovation ThérapeutiqueActicor Biotech scheduled the entry into clinical phase of the ACT-017 for late 2017- early 2018.

Contacts :

Acticor Biotech

Gilles Avenard - gilles.avenard@acticor-biotech.com

Contact Presse: NewCap

Annie-Florence Loyer - afloyer@newcap.fr

01 44 72 00 12 / 06 88 20 35 59

Léa Jacquin – ljacquin@newcap.fr

01 44 71 20 41